Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04468607 · ClinicalTrials.gov registry record · Phase 1
A Study of BLYG8824A in Participants With Locally Advanced or Metastatic Colorectal Cancer
A Phase 1 study, sponsored by Genentech.
- Completed
- Registry status
- Phase 1
- Development phase
- 46
- Enrollment target
NCT04468607 is a Phase 1 study that has completed, run by Genentech. The registered enrollment target is 46 participants.
The verdict
NCT04468607, a Phase 1 study, has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 46 participants
- Enrollment target
Study Summary
This study will evaluate the safety, tolerability, and pharmacokinetics of BLYG8824A and will make a preliminary assessment of the anti-tumor activity of BLYG8824A in patients with locally advanced or metastatic colorectal cancer.
Interventions
- DRUG BLYG8824A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2020-08-31 |
| Est. Completion | 2024-10-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04468607
The ClinicalTrials.gov registry entry for NCT04468607 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BLYG8824A is the first listed.
NCT04468607 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04468607 about?
NCT04468607 is a clinical study titled "A Study of BLYG8824A in Participants With Locally Advanced or Metastatic Colorectal Cancer". This study will evaluate the safety, tolerability, and pharmacokinetics of BLYG8824A and will make a preliminary assessment of the anti-tumor activity of BLYG8824A in patients with locally advanced or metastatic colorectal cancer.
What is the current status of trial NCT04468607?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 46 participants. The study started on 2020-08-31. Estimated completion is 2024-10-16.
What interventions are being tested in trial NCT04468607?
The interventions under investigation include: BLYG8824A (DRUG).
Who is sponsoring clinical trial NCT04468607?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.